This dark horse in the weight loss drug race is worth keeping on your watch list.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
高シグナルの見出しのみ — マクロイベント、決算、M&A、規制。リスト記事とアナリストのクリックベイトはデフォルトでフィルタ。1時間ごとに更新。
This dark horse in the weight loss drug race is worth keeping on your watch list.
Hims & Hers faces profit pressure in first-quarter 2026, though subscribers increase and a Novo Nordisk GLP-1 partnership broadens weight-loss care.
RDY stock down 5% on missing fiscal fourth-quarter 2026 earnings and revenue estimates as North America generics sales slumped.
Hims & Hers drops after posting unexpected quarterly loss
European stock markets fell in late Tuesday trading as oil prices rose after negotiations between th
Hims & Hers slashed its profitability outlook for 2026. The news sent Hims stock into free fall Tuesday morning.
By Amina Niasse and Siddhi Mahatole May 11 (Reuters) - Hims & Hers Health missed Wall Street estimates for first-quarter revenue and posted a surprise loss on Monday, as the telehealth company's shift
Investing.com -- Hims & Hers missed first-quarter earnings estimates, posting a loss as weakness in its American operations offset gains overseas.